Breast Cancer Clinical Trial
Retrospective Analysis of Drug Disposition and Response-related Genotypes in Cancer Patients and Correlation With Pharmacokinetics and Pharmacodynamics Data
|Source||National Institutes of Health Clinical Center (CC)|
|Start date||September 7, 2004|
This study is a retrospective one, exploring the hypothesis that a person's genotypic makeup
may be associated with a clinical response or toxic effect to a drug. Genetic polymorphisms,
that is, states of being able to assume different forms, that are in drug-metabolizing
enzymes, transporters, and receptors may affect a patient's response to drug therapy. To
date, there have been limited studies looking at a drug-metabolizing genotype (genetic
makeup) or phenotype (result of the genotype's interaction with the environment). However,
it is often wondered if the variations in a drug's action, that is, pharmacokinetic effect,
come from the genotype phenotype relationship.
Participants who entered previous clinical trials at the National Cancer Institute, as approved by the Central Institutional Review Board, may be eligible for this study. Studies for which pharmacokinetic analyses were or are being performed will be the source of the patient population.
Genotyping experiments will be performed through genomic DNA isolated from stored frozen serum. The genotyping results will be compared with pharmacokinetic data and clinical outcomes. Clinical data will consist of what is obtained during the course of the principal pharmacokinetic study. The results of the retrospective analyses will provide no direct benefit to the participants.
Genetic polymorphisms in drug-metabolizing enzymes, transporterss/receptors, and transcription factors might affect an individual s response to drug therapy.
Inter-individual differences in efficacy and toxicity of cancer chemotherapy are especially important given the narrow therapeutic index of these drugs.
During analysis of investigational agents, inter-individual variances in pharmacokinetics and pharmacodynamics are often noted. It is often wondered if these variances might in part be explained by genetic differences in drug metabolizing enzymes, transporters, or other criticial regulators of gene expression.
To better understand the genotype-phenotype relationship, additional analysis correlating pharmacokinetic data with relevant genotyping.
All individuals previously enrolled on IRB approved clinical trials at the National Cancer Institute.
In these retrospective studies, the association between an individual s pharmacokinetic profile and the genetic variation in their drug metabolizing enzymes and other critical regulators of gene expression will be investigated.
The hypothesis that an individual s genotypic constitution may be associated with clinical response and/or toxicity will be explored.
|Recruiting||NCT01857193 - Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer||Phase 1|
|Terminated||NCT01649258 - Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy||N/A|
|Completed||NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis||N/A|
|Active, not recruiting||NCT02371174 - Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.||N/A|
|Completed||NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)||Phase 2/Phase 3|
|Recruiting||NCT01967823 - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer||Phase 2|
|Recruiting||NCT02739425 - The Efficacy of Sentimag in Detection of Sentinel Node Biopsy||N/A|
|Not yet recruiting||NCT02767661 - Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer||Phase 3|
|Not yet recruiting||NCT03176888 - Health Benefits of HIT for Breast Cancer Patients||N/A|
|Recruiting||NCT02934126 - The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer||N/A|
|Recruiting||NCT02909751 - Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer||Phase 2|
|Recruiting||NCT02913729 - Pre- Versus Postoperative Accelerated Partial Breast Irradiation||N/A|
|Recruiting||NCT02897544 - Integrative Approaches for Cancer Survivorship 2: Project 2||N/A|
|Recruiting||NCT02897050 - Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer||Phase 2|
|Recruiting||NCT03080155 - A Study of the 3D MIRA System in Classifying Women at for Likelihood of Breast Cancer||N/A|
|Recruiting||NCT02894398 - Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant||Phase 2|
|Recruiting||NCT02903524 - Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer||Phase 4|
|Recruiting||NCT02875626 - Role of Indocyanine Green (ICG) for Detection of Sentinel Nodes in Breast Cancer||N/A|
|Recruiting||NCT02035085 - 19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction||Phase 1|
|Recruiting||NCT02689427 - Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC)||Phase 2|